US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Fidelity Disruptive Medicine ETF

32.15

+0.85392.73%

Volume:3K

Turnover:80.02K

Market Cap:52.21M

PE:- -

High:32.15

Open:31.76

Low:31.76

Close:31.30

52wk High:32.89

52wk Low:23.48

Shares:1.62M

Float Shares:1.62M

Volume Ratio:1.12

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Argenx Se : TD Cowen Raises Target Price to $1353 from $1146

THOMSON REUTERS

Argenx Se : Truist Securities Raises Target Price to $1095 from $1030

THOMSON REUTERS

Steris PLC Stock Underperforms Monday When Compared to Competitors

ADRs Close Higher; Argenx SE Climbs 16%

10x Genomics Director Sarah A. Teichmann Disposes of USD 433,106 in Common Shares

William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path

Argenx Stock Heads for Record After Blockbuster Drug Delivers Another Win

argenx SE Stock (ARGX) Moved Up by 16.67% on Aug 17: Drivers Behind the Movement

Argenx Price Target Raised to $1215.00/Share from $1075.00 by Piper Sandler

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

MT Newswires Live

Wedbush Adjusts Argenx PT to $1,150 From $1,050, Maintains Outperform Rating

MT Newswires Live

Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results

Argenx SE up over 15%, on Pace for Largest Percent Increase Since July 2023

Argenx rises 14.9%

Sector Update: Healthcare

MT Newswires Live

Argenx price target raised to $1,215 from $1,075 at Piper Sandler

argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study

MT Newswires Live

Argenx Shares Rise After Positive Results from Phase 3 Study of Efgartigimod

Thermo Fisher (TMO) Stock May Be 8% Below Fair Value On Microbiology Sale

Simply Wall St.

Lifestance Health Q2 Call Highlights Profitable Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/FMED/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FMED\",,,,,undefined,":{"symbol":"FMED","market":"US","secType":"STK","nameCN":"Fidelity Disruptive Medicine ETF","latestPrice":32.15,"timestamp":1789660292183,"preClose":31.2961,"halted":0,"volume":2506,"delay":0,"changeRate":0.02728454983208769,"floatShares":1623806,"shares":1623806,"eps":0,"marketStatus":"Trading","change":0.8539,"latestTime":"09-17 11:51:41 EDT","open":31.76,"high":32.15,"low":31.76,"amount":80024.007784,"amplitude":0.012462,"askPrice":32.16,"askSize":500,"bidPrice":32.09,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":31.2961,"sharesOutstanding":2323806,"nav":31.3164,"aum":50851758.2184,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.27,"preClose":31.2961,"latestTime":"19:30 EDT","volume":9,"amount":281.6649,"timestamp":1789601404804,"change":-0.0261,"changeRate":-0.000834,"amplitude":0},"volumeRatio":1.119972,"impliedVol":0.0666,"impliedVolPercentile":0.0055},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FMED\",,,,,undefined,":{"symbol":"FMED","floatShares":1623806,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.119972,"shares":1623806,"dividePrice":0,"high":32.15,"amplitude":0.012462,"preClose":31.2961,"low":31.76,"week52Low":23.48,"pbRate":"--","week52High":32.8877,"institutionHeld":0,"latestPrice":32.15,"eps":0,"divideRate":0,"volume":2506,"delay":0,"ttmEps":0,"open":31.76,"prevYearClose":27.05,"prevWeekClose":31,"prevMonthClose":31.775,"prevQuarterClose":28.525,"fiveDayClose":30.8414,"twentyDayClose":32.8877,"sixtyDayClose":26.3894},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FMED\",params:#limit:5,,,undefined,":[{"date":"2024-12-20","symbol":"FMED","amount":0.112,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Fidelity Disruptive Medicine ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-24"},{"date":"2024-06-21","symbol":"FMED","amount":0.001,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-21","defaultRemindTime":1718976600000,"name":"Fidelity Disruptive Medicine ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-25","payableDate":"2024-06-21","currency":"USD","dateTimestamp":1718942400000,"payDate":"2024-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FMED\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-21","recordDate":"2024-06-21","paymentDate":"2024-06-25","value":0.001,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-24","value":0.112,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FMED\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660451398","title":"Argenx Se : TD Cowen Raises Target Price to $1353 from $1146","url":"https://stock-news.laohu8.com/highlight/detail?id=2660451398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660451398?lang=en_us&edition=fundamental","pubTime":"2026-08-18 12:16","pubTimestamp":1787026573,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44E0RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","LU0889565916.HKD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0823416689.USD","LU1983260115.SGD","ARGX","IE0034235188.USD","BK4139","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IBB","TBXU","IE0002141913.USD","BK4505","FMED","LU0109394709.USD","LU2324357040.USD","IE0009355771.USD","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456165","title":"Argenx Se : Truist Securities Raises Target Price to $1095 from $1030","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456165?lang=en_us&edition=fundamental","pubTime":"2026-08-18 10:39","pubTimestamp":1787020796,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44E0QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","BK4139","BK4585","LU1983260115.SGD","ARGX","IBB","FMED","IE00BJT1NW94.SGD","TBXU","IE00BFTCPJ56.SGD","BK4588","IE00B4R5TH58.HKD","LU2324357040.USD","LU0889565916.HKD","LU0109394709.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU0823416689.USD","BK4505","IE0034235188.USD","IE00BJJMRZ35.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660243207","title":"Steris PLC Stock Underperforms Monday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660243207","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660243207?lang=en_us&edition=fundamental","pubTime":"2026-08-18 05:07","pubTimestamp":1787000820,"startTime":"0","endTime":"0","summary":"DJ Steris PLC Stock Underperforms Monday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Steris PLC  slid 1.51% to $229.75 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.52% to 7,745.06 and Dow Jones Industrial Average  falling 0.51% to 53,459.78.This was the stock's fifth consecutive day of losses.Steris PLC closed 14.73% below its 52-week high of $269.44, which the company reached on January 16th.The stock underperformed when compared to some of its competitors Monday, as Thermo Fisher Scientific Inc.  fell 0.47% to $585.51, Danaher Corp.  rose 0.09% to $202.63, and Becton Dickinson & Co.  fell 0.71% to $182.09.Trading volume  remained 138,976 below its 50-day average volume of 807,197.Data source: Dow Jones Market Data, FactSet. Data compiled August 17, 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0109391861.USD","IE00BFXG1179.USD","LU1989771016.USD","LU1720051017.SGD","BK4121","SGXZ23171101.USD","LU0006061336.USD","IE00B1BXHZ80.USD","LU0943347566.SGD","LU1267930573.SGD","DHR","LU0208291251.USD","LU2106854487.HKD","LU0057025933.USD","LU0128525929.USD","LU0072461881.USD","LU0124676726.USD","LU1150488135.SGD","TMO","LU0289739343.SGD","HRTS","BDX","BK4581","LU2063271972.USD","TMED","LU2041044095.USD","LU2023250504.SGD","LU2211815571.USD","BK4566","LU0648000940.SGD","LU1059921491.USD","IE00BZ1G4Q59.USD","LU0432979614.USD","LU1064131342.USD","LU0345770308.USD","GNMX","IE0034235188.USD","LU0477156797.USD","LU1923622291.USD","LU2764263039.SGD","FMED","LU1670628061.USD","STE","LU1291159041.SGD","IHI","LU0878866978.SGD","LU0070302665.USD","LU0820561909.HKD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432656","title":"ADRs Close Higher; Argenx SE Climbs 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432656?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:31","pubTimestamp":1786998660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Monday, as the S&P/BNY Mellon index of American","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","TBXU","ARGX","LU2324357040.USD","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","SCHY","BK4505","LU0889565916.HKD","LU0109394709.USD","LU0823416689.USD","IE00B2B36J28.USD","BK4139","FMED","LU1983260115.SGD","IE0002141913.USD","BK4585","IE00BFTCPJ56.SGD","LU0320765992.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660434081","title":"10x Genomics Director Sarah A. Teichmann Disposes of USD 433,106 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660434081","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660434081?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:09","pubTimestamp":1786997366,"startTime":"0","endTime":"0","summary":"10x Genomics director Sarah A. Teichmann disposes of USD 433,106 in common shares10x Genomics director Sarah A. Teichmann sold 7,551 Class A common shares on Aug. 13-14.Sales priced at $57.29 and $57.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL9D8HHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"10x Genomics Director Sarah A. Teichmann Disposes of USD 433,106 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","FMED","ARKG","TXG","LU1861558580.USD","BK4588","LU1861559042.SGD","BK4585","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660888434","title":"William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path","url":"https://stock-news.laohu8.com/highlight/detail?id=2660888434","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660888434?lang=en_us&edition=fundamental","pubTime":"2026-08-18 02:20","pubTimestamp":1786990827,"startTime":"0","endTime":"0","summary":"William Blair notes that Argenx (ARGX) announced top-line results from the Phase III ALKIVIA trial of Vyvgart in autoimmune myositis, showing a cli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/william-blair-says-argenxs-alkivia-results-boost-confidence-in-vyvgart-dm-path-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/william-blair-says-argenxs-alkivia-results-boost-confidence-in-vyvgart-dm-path-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","FMED","LU2324357040.USD","LU0320765992.SGD","ARGX","IBB","BK4505","LU0823416689.USD","TBXU","LU0109394709.USD","LU1983260115.SGD","BK4588","BK4139","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE0034235188.USD","IE0009355771.USD","LU0889565916.HKD","IE00B2B36J28.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431479","title":"Argenx Stock Heads for Record After Blockbuster Drug Delivers Another Win","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431479","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660431479?lang=en_us&edition=fundamental","pubTime":"2026-08-18 02:04","pubTimestamp":1786989840,"startTime":"0","endTime":"0","summary":"Argenx's autoimmune drug Vyvgart achieved blockbuster status in just its second full year on the market. Now, the Dutch biotech is looking to expand use of the drug to treat more conditions.Argenx on ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","TBXU","BK4588","BK4585","LU1983260115.SGD","BK4505","FMED","BK4139","IE00BJT1NW94.SGD","LU2324357040.USD","LU0320765992.SGD","ARGX","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","LU0823416689.USD","IE0002141913.USD","LU0109394709.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660650439","title":"argenx SE Stock (ARGX) Moved Up by 16.67% on Aug 17: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660650439","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660650439?lang=en_us&edition=fundamental","pubTime":"2026-08-18 00:15","pubTimestamp":1786983324,"startTime":"0","endTime":"0","summary":"• Argenx announced positive Phase 3 ALKIVIA study results for VYVGART Hytrulo in myositis.\n• The company reported $4.15 billion in annual revenue and $1.29 billion in net profit.\n• Analysts issued Buy ratings with an average price target of $1083.77.","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262112694-market-movers-argx-20260817","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4588","LU0823416689.USD","TBXU","BK4139","FMED","BK4505","LU1983260115.SGD","IBB","IE00B2B36J28.USD","LU0320765992.SGD","LU0109394709.USD","IE0002141913.USD","BK4585","IE0034235188.USD","ARGX","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660439344","title":"Argenx Price Target Raised to $1215.00/Share from $1075.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2660439344","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660439344?lang=en_us&edition=fundamental","pubTime":"2026-08-18 00:07","pubTimestamp":1786982820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARGX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","ARGX","BK4585","BK4505","IE0002141913.USD","LU2324357040.USD","IE00BFTCPJ56.SGD","LU0823416689.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","FMED","IE00BJJMRZ35.SGD","IE0034235188.USD","LU0320765992.SGD","BK4588","BK4139","IE00BJT1NW94.SGD","IBB","TBXU","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660323436","title":"European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2660323436","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660323436?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:12","pubTimestamp":1786979555,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts started the week tracking modestly higher late Monday morning, rising 0.31% to 1,970.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies argenx  and DBV Technologies , which climbed 16% and 5.1% respectively. They were followed by telecommunications company Nokia  and biopharmaceutical company Cellectis , which advanced 2.5% and 2% respectively.The decliners from continental Europe were led by medical device maker EDAP TMS  and internet browser company Opera , which dropped 4.6% and 2.7% respectively. They were followed by brewing company Anheuser-Busch InBev  and consumer goods company Unilever , which lost 2.4% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics  and biopharmaceutical company Akari Therapeutics , which rose 6.3% and 2.8% respectively. They were followed by biopharmaceutical companies GSK  and Bicycle","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","IEUR","LU0823416689.USD","IE00B4R5TH58.HKD","UL","BK4592","IE00BJJMRZ35.SGD","NOK","MREO","BK4588","BUD","IE0002141913.USD","LU0889565916.HKD","BK4139","BCYC","AKTX","BK4169","FMED","BK4505","DEO","FOCL","AUTL","GSK","DGE.UK","IE00BMPRXN33.USD","IE00BFTCPJ56.SGD","LFGY","DBVT","ULVR.UK","GSKH","BK4532","ARGX","WPP","IBB","OPRA","BK4117","TBXU","BK4107","BK4007","BK4009","NCNA","UN","AFG","WPP.AU","GSK.UK","LU0006061336.USD","BUD.AU","CLLS","LNOK","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660543552","title":"Wedbush Adjusts Argenx PT to $1,150 From $1,050, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660543552","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660543552?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:35","pubTimestamp":1786977309,"startTime":"0","endTime":"0","summary":"Argenx (ARGX) has an average rating of buy and mean price target of $1,094.70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2324357040.USD","ARGX","IE00B4R5TH58.HKD","BK4588","BK4139","LU0889565916.HKD","BK4505","IE00BJJMRZ35.SGD","LU0823416689.USD","LU1983260115.SGD","IE0034235188.USD","TBXU","LU0109394709.USD","IE00BJT1NW94.SGD","BK4585","IE00BFTCPJ56.SGD","FMED","IE00B2B36J28.USD","IE0002141913.USD","IE0009355771.USD","LU0320765992.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433030","title":"Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660433030?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:11","pubTimestamp":1786975871,"startTime":"0","endTime":"0","summary":"Argenx SE stock was up 15.25% on Monday after the company posted results from its ALKIVIA Phase 3 study.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/argenx-se-argx-stock-soars-15-on-positive-phase-3-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/argenx-se-argx-stock-soars-15-on-positive-phase-3-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LU0320765992.SGD","LU0109394709.USD","BK4585","ARGX","IE00BJT1NW94.SGD","LU1983260115.SGD","BK4505","LU0823416689.USD","TBXU","LU0889565916.HKD","LU2324357040.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","FMED","IE0009355771.USD","IE00B2B36J28.USD","IE0034235188.USD","BK4139","IE00B4R5TH58.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433417","title":"Argenx SE up over 15%, on Pace for Largest Percent Increase Since July 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433417","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660433417?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:08","pubTimestamp":1786975680,"startTime":"0","endTime":"0","summary":"argenx SE Sponsored ADR  is currently at $979.54, up $128.25 or 15.07%--Would be new all-time closing high --Would be the first record close since July 2, 2026, when it closed at $939.68--On pace for largest percent increase since July 17, 2023, when it rose 27.79%--Snaps a two day losing streak--Up 14.72% month-to-date--Up 16.48% year-to-date--Up 48.12% from 52 weeks ago , when it closed at $661.32--Would be a new 52-week closing high--Up 49.12% from its 52-week closing low of $656.89 on Aug. 19, 2025--Traded as high as $982.95; new all-time intraday high --Up 15.47% at today's intraday high; largest intraday percent increase since July 17, 2023, when it rose as much as 31.54%All data as of 10:02:39 AM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","FMED","LU2324357040.USD","LU0320765992.SGD","ARGX","IBB","BK4505","LU0823416689.USD","TBXU","LU0109394709.USD","LU1983260115.SGD","BK4588","BK4139","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE0034235188.USD","IE0009355771.USD","LU0889565916.HKD","IE00B2B36J28.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660743398","title":"Argenx rises 14.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660743398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660743398?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:00","pubTimestamp":1786975211,"startTime":"0","endTime":"0","summary":"Argenx (ARGX) is up 14.9%, or $126.60 to $977.89. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/argenx-rises-14-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/argenx-rises-14-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","IBB","IE0009355771.USD","IE00BJT1NW94.SGD","TBXU","LU1983260115.SGD","BK4139","IE00BFTCPJ56.SGD","BK4505","BK4585","ARGX","BK4588","FMED","LU0109394709.USD","LU2324357040.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0823416689.USD","IE0034235188.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480066","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480066","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660480066?lang=en_us&edition=fundamental","pubTime":"2026-08-17 21:04","pubTimestamp":1786971840,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF  0.5% lower and the iShares Biotechnology ETF  up 0.2%.Argenx  shares were nearly 12% higher after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4550","FDN","BK4137","ARGX","LU0823416689.USD","LU2324357040.USD","IE00B64PRP62.GBP","LU1983260115.SGD","LABU","IE00BJT1NW94.SGD","BK4139","BK4585","IE00BGHQF748.EUR","XBI","XLV","IE00BJJMRZ35.SGD","LU1894683348.USD","BK4505","IBB","IE0009355771.USD","IE00B4R5TH58.HKD","LU0061475181.USD","TBXU","IE0034235188.USD","LU1894683264.USD","IE00B3QW5Z07.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","STT","FMED","HCSG","LU0029874061.USD","BK4581","IE0002141913.USD","BK4588","LU0128526141.USD","LU1883839398.USD","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484769","title":"Argenx price target raised to $1,215 from $1,075 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484769","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484769?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:13","pubTimestamp":1786965211,"startTime":"0","endTime":"0","summary":"Piper Sandler raised the firm’s price target on Argenx (ARGX) to $1,215 from $1,075 and keeps an Overweight rating on the shares. With Q2 2026 repo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/argenx-price-target-raised-to-1215-from-1075-at-piper-sandler-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/argenx-price-target-raised-to-1215-from-1075-at-piper-sandler-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","ARGX","BK4585","BK4505","IE0002141913.USD","LU2324357040.USD","IE00BFTCPJ56.SGD","LU0823416689.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","FMED","IE00BJJMRZ35.SGD","IE0034235188.USD","LU0320765992.SGD","BK4588","BK4139","IE00BJT1NW94.SGD","IBB","TBXU","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483685","title":"argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483685","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660483685?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:25","pubTimestamp":1786955131,"startTime":"0","endTime":"0","summary":"argenx  said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met main goal.The company said the patients treated with the drug showed a statistically significant improvement in mean total improvement score at week 52 compared with placebo.Treatment benefits emerged as early as week 4 and were sustained through the 52-week treatment period, including during steroid tapering, the company said.argenx said the primary endpoint was also met in patients with immune-mediated necrotizing myopathy, while dermatomyositis patients showed a similar improvement, although it did not reach statistical significance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002141913.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0823416689.USD","IE0009355771.USD","IE0034235188.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4505","LU0109394709.USD","BK4585","LU0889565916.HKD","IBB","BK4588","ARGX","LU2324357040.USD","IE00BJJMRZ35.SGD","LU1983260115.SGD","TBXU","BK4139","FMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660948803","title":"Argenx Shares Rise After Positive Results from Phase 3 Study of Efgartigimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2660948803","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660948803?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:08","pubTimestamp":1786954080,"startTime":"0","endTime":"0","summary":"Shares in Argenx rose after the European pharmaceutical company reported positive results from the phase 3 trial of Efgartigimod for the treatment of autoimmune myositis.In early morning trading, shar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Argenx Shares Rise After Positive Results from Phase 3 Study of Efgartigimod","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IBB","IE0009355771.USD","BK4588","IE0034235188.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0823416689.USD","BK4139","BK4505","ARGX","LU1983260115.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","FMED","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","TBXU","IE00B4R5TH58.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828109","title":"Thermo Fisher (TMO) Stock May Be 8% Below Fair Value On Microbiology Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828109","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828109?lang=en_us&edition=fundamental","pubTime":"2026-08-17 08:35","pubTimestamp":1786926913,"startTime":"0","endTime":"0","summary":"Thermo Fisher Scientific stock has delivered a 20.7% gain over the past year, and the latest checks suggest it now sits close to its estimated intrinsic value rather than looking clearly cheap or clearly expensive.\n\nThermo Fisher Scientific is up 20.7% over the past 12 months, which puts more focus on whether current buyers are paying a fair price for the cash flows that the business may generate.\nThe recent sale of the microbiology business and ongoing work in proteomics and precision...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/97023-main-header/1756189961534","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/97023-main-header/1756189961534"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-tmo-stock-may-be-8-below-fair-value-on-microbi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-tmo-stock-may-be-8-below-fair-value-on-microbi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1670628061.USD","IE00BQXX3F31.USD","LU1153585028.USD","LU0345770308.USD","BK4535","LU0011850046.USD","FMED","LU0640476718.USD","LU2041044095.USD","SPHQ","LU2063271972.USD","LU2720916845.USD","LU0114720955.EUR","LU0320765489.SGD","LU1988902786.USD","LU2125910336.SGD","LU2092937221.SGD","BK4533","LU2264538146.SGD","LU1815333072.USD","LU2360108059.USD","IE00B19Z9505.USD","IE00B1BXHZ80.USD","BK4566","LU1923622291.USD","BK4581","TMO","LU1712237335.SGD","LU0128525929.USD","IE00BJT1NW94.SGD","LU1720051017.SGD","LU2468319806.SGD","LU0070302665.USD","DCF","LU0957791311.USD","LU1854103824.USD","LU0310800379.SGD","LU2764263039.SGD","IE00BKPKM429.USD","IE00B2B36J28.USD","IE00BQXX3D17.EUR","LU0061474960.USD","LU2764262908.HKD","HRTS","IE00B19Z8X17.USD","TMED","IE0034235188.USD","LU0122379950.USD","BK4534","LU0316494557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659794001","title":"Lifestance Health Q2 Call Highlights Profitable Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2659794001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659794001?lang=en_us&edition=fundamental","pubTime":"2026-08-16 08:15","pubTimestamp":1786839326,"startTime":"0","endTime":"0","summary":"Lifestance Health Group, Inc. (($LFST)) has held its Q2 earnings call. Read on for the main highlights of the call. Lifestance Health Group’s lates...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lifestance-health-q2-call-highlights-profitable-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lifestance-health-q2-call-highlights-profitable-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4535","JOYT","VGFPF","VOTE","BK4539","FEBU","PMDE","DECU","FMED","RGLO","GXDW","LFST"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}